Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30793338 | 0.87 | MAPT (0.37) | MEN1KMT2AMAPTGPR119HPGD | |
| SCHEMBL24535292 | 0.87 | GPR119 (0.39) | MEN1KMT2AMAPTGPR119HPGD | |
| SCHEMBL30793677 | 0.86 | MEN1 (0.38) | MEN1KMT2AADORA1MAPTGPR119 | |
| SCHEMBL25336741 | 0.86 | MEN1 (0.38) | MEN1KMT2AADORA1MAPTGPR119 | |
| SCHEMBL30793460 | 0.85 | MEN1 (0.38) | MEN1KMT2AADORA1MAPTGPR119 | |
| SCHEMBL25335687 | 0.85 | MEN1 (0.43) | MEN1KMT2AADORA1MAPTHPGD | |
| SCHEMBL31323684 | 0.85 | ADORA1 (0.42) | MEN1KMT2AADORA1MAPTGPR119 | |
| SCHEMBL30793750 | 0.84 | ADORA1 (0.39) | MEN1KMT2AADORA1MAPTHPGD | |
| SCHEMBL30793120 | 0.84 | GPR119 (0.37) | MEN1KMT2AMAPTGPR119NR1H2 | |
| SCHEMBL30793426 | 0.83 | MEN1 (0.39) | MEN1KMT2AADORA1MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025006753-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 948/4885KMT2A 1207/4885ADORA1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.